Role of arachidonic cascade in COVID-19 infection: A review
- PMID: 33592322
- PMCID: PMC7882227
- DOI: 10.1016/j.prostaglandins.2021.106539
Role of arachidonic cascade in COVID-19 infection: A review
Abstract
The World Health Organization has described the 2019 Coronavirus disease caused by an influenza-like virus called SARS-CoV-2 as a pandemic. Millions of people worldwide are already infected by this virus, and severe infection causes hyper inflammation, thus disrupting lung function, exacerbating breath difficulties, and death. Various inflammatory mediators bio-synthesized through the arachidonic acid pathway play roles in developing cytokine storms, injuring virus-infected cells. Since pro-inflammatory eicosanoids, including prostaglandins, and leukotrienes, are key brokers for physiological processes such as inflammation, fever, allergy, and pain but, their function in COVID-19 is not well defined. This study addresses eicosanoid's crucial role through the arachidonic pathway in inflammatory cascading and recommends using bioactive lipids, NSAIDs, steroids, cell phospholipase A2 (cPLA2) inhibitors, and specialized pro-resolving mediators (SPMs) to treat COVID-19 disease. The role of soluble epoxide hydrolase inhibitors (SEHIs) in promoting the activity of epoxyeicosatrienoic acids (EETs) and 17-hydroxide-docosahexaenoic acid (17-HDHA) is also discussed. Additional research that assesses the eicosanoid profile in COVID-19 patients or preclinical models generates novel insights into coronavirus-host interaction and inflammation regulation.
Keywords: Arachidonic cascade; COVID-19; COX; NSAID.
Copyright © 2021 Elsevier Inc. All rights reserved.
Figures




Similar articles
-
Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?Cancer Metastasis Rev. 2020 Jun;39(2):337-340. doi: 10.1007/s10555-020-09889-4. Cancer Metastasis Rev. 2020. PMID: 32385712 Free PMC article.
-
Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?Am J Pathol. 2020 Sep;190(9):1782-1788. doi: 10.1016/j.ajpath.2020.06.010. Epub 2020 Jul 8. Am J Pathol. 2020. PMID: 32650004 Free PMC article. Review.
-
Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.Biochem Pharmacol. 2023 Mar;209:115437. doi: 10.1016/j.bcp.2023.115437. Epub 2023 Jan 30. Biochem Pharmacol. 2023. PMID: 36731803 Free PMC article. Review.
-
Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.Arch Pharm Res. 2021 Jan;44(1):84-98. doi: 10.1007/s12272-020-01299-y. Epub 2021 Jan 4. Arch Pharm Res. 2021. PMID: 33398691 Free PMC article. Review.
-
Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.Med Hypotheses. 2020 Dec;145:110340. doi: 10.1016/j.mehy.2020.110340. Epub 2020 Oct 8. Med Hypotheses. 2020. PMID: 33069094 Free PMC article.
Cited by
-
Polyunsaturated Fatty Acid Imbalance-A Contributor to SARS CoV-2 Disease Severity.J Nutr Metab. 2025 Mar 24;2025:7075883. doi: 10.1155/jnme/7075883. eCollection 2025. J Nutr Metab. 2025. PMID: 40166706 Free PMC article. Review.
-
Metabolite profile of COVID-19 revealed by UPLC-MS/MS-based widely targeted metabolomics.Front Immunol. 2022 Jul 18;13:894170. doi: 10.3389/fimmu.2022.894170. eCollection 2022. Front Immunol. 2022. PMID: 35924246 Free PMC article.
-
Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy.Front Mol Biosci. 2024 Feb 22;11:1338567. doi: 10.3389/fmolb.2024.1338567. eCollection 2024. Front Mol Biosci. 2024. PMID: 38455763 Free PMC article. Review.
-
COVID-19, Blood Lipid Changes, and Thrombosis.Biomedicines. 2023 Apr 15;11(4):1181. doi: 10.3390/biomedicines11041181. Biomedicines. 2023. PMID: 37189799 Free PMC article. Review.
-
1-L Transcription of SARS-CoV-2 Spike Protein S1 Subunit.Int J Mol Sci. 2024 Apr 18;25(8):4440. doi: 10.3390/ijms25084440. Int J Mol Sci. 2024. PMID: 38674024 Free PMC article.
References
-
- Chan J.F., Kok K., Zhu Z., Chu H., Kai-wang K., Yuan S., Yuen K., Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., Tan W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017. - DOI - PMC - PubMed
-
- Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., Chen C., Jin L., Yang R., Wang Q., Zhou S., Wang R., Liu H., Luo Y., Liu Y., Shao G., Li H., Tao Z., Yang Y., Deng Z., Liu B., Ma Z., Zhang Y., Shi G., Lam T.T.Y., Wu J.T., Gao G.F., Cowling B.J., Yang B., Leung G.M., Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed
-
- Zhou P., Lou Yang X., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Di Jiang R., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous